Pertuzumab study in the neoadjuvant setting for HER2-positive nonmetastatic breast cancer in Australia (PeRSIA) - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36005450/
The pertuzumab study in the neoadjuvant setting for HER2+ nonmetastatic breast cancer in Australia (PeRSIA-ML39622) is an analysis of safety and effectiveness data from the pertuzumab patient registry. Although the prognosis of patients with early stage HER2+ breast cancer has been greatly improved ...
Conclusion/Relevance: Our study is the first to capture real-world data on the use of pertuzumab in the neoadjuvant setting in Australia. The effectiveness and safety data are consistent with those reported in clinical trials of pertuzumab in patients with HER2 breast cancer, with no new safety concerns.
-
Albert DekkerSeptember 09, 2022not sure how relevant that is for US. This is clearly example that socialized medicine is at least 5 year behind